Denali Therapeutics’ (DNLI) Outperform Rating Reiterated at William Blair

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “outperform” rating reissued by equities researchers at William Blair in a note issued to investors on Wednesday,RTT News reports.

Several other research firms have also issued reports on DNLI. HC Wainwright reduced their target price on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research note on Monday, December 16th. JPMorgan Chase & Co. lowered their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 7th. Jefferies Financial Group upped their price target on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Finally, Robert W. Baird initiated coverage on shares of Denali Therapeutics in a report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price objective for the company. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $38.91.

Denali Therapeutics Stock Up 0.8 %

NASDAQ DNLI opened at $21.67 on Wednesday. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33. The firm has a market capitalization of $3.12 billion, a P/E ratio of -7.85 and a beta of 1.39. The company has a 50-day moving average price of $23.32 and a 200-day moving average price of $24.74.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the firm earned ($0.72) EPS. As a group, equities research analysts anticipate that Denali Therapeutics will post -2.73 EPS for the current year.

Insider Activity at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,020 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the transaction, the director now owns 111,056 shares of the company’s stock, valued at approximately $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Carole Ho sold 12,255 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the sale, the insider now owns 178,580 shares in the company, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 64,518 shares of company stock worth $1,469,382. Insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

A number of large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its stake in Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after buying an additional 14,324 shares during the period. Principal Financial Group Inc. increased its position in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after acquiring an additional 149,939 shares during the period. Franklin Resources Inc. raised its stake in shares of Denali Therapeutics by 3.8% during the third quarter. Franklin Resources Inc. now owns 80,041 shares of the company’s stock valued at $2,148,000 after acquiring an additional 2,901 shares in the last quarter. Barclays PLC boosted its holdings in shares of Denali Therapeutics by 101.4% in the third quarter. Barclays PLC now owns 255,883 shares of the company’s stock valued at $7,454,000 after purchasing an additional 128,823 shares during the period. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in shares of Denali Therapeutics in the third quarter valued at approximately $1,894,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.